BeiGene price target raised to $290 from $285 at Citi

Citi raised the firm’s price target on BeiGene to $290 from $285 and keeps a Buy rating on the shares. The firm says BeiGene’s announcement that it has regained full tislelizumab rights from Novartis did not come as a complete surprise given Novartis had also handed back rights to ociperlimab earlier this summer. The analyst updated the company’s model after tislelizumab was approved in Europe.